Turning scientific research into a useful product or service takes more than a promising laboratory result. It requires engineering, validation, funding, regulation and a route to customers. On 12 November, the Spanish National Research Council presented 25 research-based business projects at its Demo Day, bringing research teams into contact with investors, companies and organisations that may help move the work towards the market.
A demo day for research-based ventures
The CSIC event was organised as part of its Converge initiative, which supports the transfer of research into society and the economy. The Demo Day gave 25 projects a chance to explain their technologies and development plans to an audience that included more than 50 representatives from investors, companies and other organisations. The format is designed to create conversations, not to declare every project a finished business.
That distinction matters. A research project may have a working prototype but still need testing, certification, manufacturing partners or a clearer commercial model. A demo day can help a team identify the next gap and find people with the experience to address it. The most valuable result may be a partnership or a follow-up meeting rather than an immediate investment announcement.
Twenty-five projects across sectors
The projects presented by CSIC covered a wide range of fields, including health and biomedicine, advanced therapies, diagnostics, artificial intelligence, agriculture, robotics, sensors, energy, advanced materials and sustainability. The breadth shows how public research can contribute to technologies that affect very different parts of daily life, from medical treatment to industrial processes and environmental monitoring.
Some projects are closer to a product than others. A diagnostic tool may need clinical validation, while a new material may need industrial-scale testing. A digital platform may need data partnerships and a clear route into an existing workflow. Bringing these projects together allows investors and companies to compare opportunities, but it also makes clear that each field has its own technical and regulatory path.
What investors and researchers need from each other
Researchers often know a technology in great detail but may have limited experience in manufacturing, pricing, sales or customer support. Investors and companies bring a different set of questions: who needs the product, what problem does it solve, how large is the market and what evidence shows that the solution works? A useful conversation connects those questions without asking a research team to abandon the scientific purpose of its work.
Funding is only one part of the exchange. A company may provide access to a test environment, a supplier may help refine a component, or a hospital may help evaluate a medical technology. These partnerships can reduce the distance between a laboratory result and a product that can be used safely and reliably. The right partner depends on the maturity and needs of each project.
From prototype to a viable product
Commercialisation involves stages that are not always visible in a presentation. Teams need to test whether a technology works outside controlled laboratory conditions, understand the cost of producing it, protect intellectual property where appropriate and meet the rules that apply to the sector. Medical devices and therapies face different requirements from agricultural sensors or software tools, so there is no single route from research to market.
An event like Demo Day can help make those stages clearer. Feedback from people who have launched products can reveal where a project needs more evidence or a different business model. It can also help researchers decide whether to form a spin-off, license a technology to an existing company or continue developing the work within a research institution.
Why the event matters for Spanish innovation
Public research creates knowledge that may have value far beyond academic publication. The challenge is building the connections that allow that knowledge to be used. By presenting projects to investors and companies, CSIC is trying to make those connections more systematic and to show that scientific capability can become part of Spain’s innovation economy.
The event should not be read as proof that all 25 projects are already commercial successes. It is a snapshot of a pipeline: ideas at different stages, teams looking for partners and technologies that need further work. That is still important. A healthy innovation system needs places where research can be tested against real-world needs before a product is promised to customers.
The value of CSIC Demo Day is in making the transition from research to application visible. It creates a setting where scientists can explain what they have built and where potential partners can ask what is needed next. For readers, the event is a reminder that innovation is usually a process of validation and collaboration, not a single breakthrough moment.
